Travere Therapeutics price target raised to $20 from $18 at Barclays
The Fly

Travere Therapeutics price target raised to $20 from $18 at Barclays

Barclays raised the firm’s price target on Travere Therapeutics (TVTX) to $20 from $18 and keeps an Overweight rating on the shares post the Q3 report. The firm says Filspari beat despite a slow-down in new starts.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App